Martin Page
Senior Vice President Regulatory Affairs
- History & Future
- Vaccinogen Timeline
- Chairman's Letter
- What is OncoVAX®?
- Driving Principles
- Management
- Facilities
- Publications
Martin Page brings to Vaccinogen more than 30 years of experience with all major regulatory authorities, especially the European Medicines Agency, and its predecessors, and the U.S. Food and Drug Administration (FDA). Since March 2003, he has been directly involved with OncoVax®’s success as the Sr. V.P. of Global Regulatory Affairs for Intracel. His product experience includes biotechnology products (monoclonal antibodies, rDNA products) as well as traditional pharmaceuticals (oral, topical and parenteral dose forms).
Highlights of Martin Page’s vast career include Sr. V.P., Worldwide Regulatory Affairs, at Centocor Inc., where they received rapid approvals with both the FDA and EMEA of a major new antiplatelet entity (ReoPro – abciximab) for use in cardiovascular interventions and an anti-TNF agent (Remicade – infliximab) for Crohn’s disease and rheumatoid arthritis. While at Schering-Plough International, as V.P., Scientific Affairs, Martin was responsible for the international medical department, pharmaceutical development laboratories and the quality assurance function as well as regulatory affairs. He was involved in the early approvals in international markets of the non-sedating antihistamine Claratin (loratadine) and INTRON-A (alpha interferon). Mr. Page received a B.A. and M.A. in natural sciences from Queens’ College, Cambridge University, in the UK.